Inhibitory effect of teriparatide in knee osteoarthritis

JRCT ID: jRCTs051180095

Registered date:06/03/2019

Basic Information

• Recruitment status: Not Recruiting
• Health condition(s) or Problem(s) studied: Knee osteoarthritis, osteoporosis
• Date of first enrollment: 15/10/2018
• Target sample size: 60
• Study type: Interventional

Intervention(s)

Arm A: Weekly treatment of teriparatide (56.5 micro g) for 24 months.
Arm B: Daily treatment f Vitamin D3 analog 0.25, 0.5, 0.75 or 1.0 micro g) for 24 months.

Outcome(s)

• Primary Outcome: Disease progression by X ray (bone trabecular integrity, Joint space narrowing, width)

Secondary Outcome

Cartilage volume by MRI,
Grade of osteoarthritis by Xray (Kellgren-Lawrence grade)
Clinical outcomes (WOMAC, KSS)

Key inclusion & exclusion criteria

• Age minimum: >= 60age old
• Age maximum: Not applicable
• Gender: Female

Include criteria

Patient who was diagnosed as osteoporosis with high risk of fracture
Patient who was diagnosed as osteoarthritis of the knee with Kellgren-Lawrence grade 2 or 3.
Patient who has knee pain.

Exclude criteria

Patient who uses corticosteroid
The reason of the pain is other than osteoarthritis
Patient with dementia
Patient who has contraindication for the drug which is used in this study.

Related Information

• Primary Sponsor: Matsuda Shuichi
• Source(s) of Monetary Support: Asahi Kasei Pharma Corporation